Loring Wolcott & Coolidge Fiduciary Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3	Closed	-$2K	–	770
2021 Q2	$2K	Buy	+3	New	+$1.83K	﹤0.01%	836
2021 Q1	–	Sell	-5	Closed	-$3K	–	352
2020 Q4	$3K	Buy	+5	New	+$2.85K	﹤0.01%	720
2017 Q4	–	Sell	-6	Closed	-$1K	–	750
2017 Q3	$1K	Buy	+6	New	+$1.35K	﹤0.01%	697

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's BIO Position: Q3 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2021, closing a stake of 3 shares — an estimated $2K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in BIO in Q3 2017 and held it in 3 quarters. The position peaked at $3K in Q4 2020. 508 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2021 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 3 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $2K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2017 and held it in 3 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Bio-Rad Laboratories Class A position peaked at $3K in Q4 2020.
508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.